Rubicon Research
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Rubicon Research is strategically positioned for growth, bolstered by management's focus on high-value specialty products and significant R&D investments. The recent acquisition of a New Jersey manufacturing site and the ramp-up of the Pithampur facility are pivotal developments that enhance operational capabilities and market reach, particularly in the U.S. market. Management's upward revision of EBITDA margin guidance to 23% for FY27 reflects confidence in these initiatives, despite potential cost pressures from geopolitical factors and execution risks associated with the Arinna acquisition. Vista's financial outlook anticipates moderate revenue growth, supported by improving margins and a premium valuation, with an expected upside of approximately 28.68%. The expanding Pharma APIs and CRAMS industry, alongside favorable macroeconomic conditions in India, further underpins Rubicon's growth trajectory. However, investors should remain vigilant regarding potential disruptions from raw material shortages and regulatory challenges. Over the next 12-24 months, key opportunities include the commercialization of new facilities and product developments, while watchpoints include execution risks and inflationary pressures on input costs
Why We Like This Stock
- Strategic acquisitions and R&D investments are expected to enhance operational capabilities and market reach
- Management's upward revision of EBITDA margin guidance reflects confidence in growth initiatives
- The expanding Pharma APIs and CRAMS industry presents significant growth opportunities
Things To Watch Out For
- Execution risks related to the Arinna acquisition could impact competitive positioning
- Potential cost pressures from geopolitical conditions may affect margins
- Regulatory compliance challenges could hinder market expansion efforts
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 854 | 1,284 | 1,754 | 1,992 | 2,389 |
| Profit Before Tax (Cr.) | 103 | 194 | 321 | 377 | 454 |
| PBT Margin | 12.1% | 15.1% | 18.3% | 18.9% | 19.0% |
| Net Profit (Cr.) | 90 | 132 | 235 | 283 | 340 |
| Earnings Per Share | 5.4 | 8.0 | 14.2 | 17.1 | 20.6 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Motilal Oswal | ▲ Buy | 1,915 | 15-Aug-2026 |
Company Overview
Show Company Profile
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.